Roche has terminated recruitment in the Phase II SHIELD DMD study (NCT06450639) evaluating satralizumab (trade name: Enspryng), an interleukin-6 (IL-6) receptor-targeting monoclonal antibody, for bone health in patients with Duchenne muscular dystrophy (DMD), according to a company communication to patient organizations.
The multinational trial was assessing whether IL-6 pathway inhibition could mitigate progressive bone mineral density (BMD) loss associated with long-term corticosteroid use in DMD. Roche said enrolled participants may continue through the interim six-month BMD data collection milestone, expected in H2 2026, after which the study and further development of satralizumab in this indication will be discontinued.
The SHIELD DMD trial was designed as a Phase II interventional study enrolling fewer than 30 patients across Denmark, Italy, Poland, Spain, Ukraine, and the US. The primary objective was to evaluate changes in BMD at six months as a surrogate marker of skeletal fragility risk in pediatric and adolescent patients with genetically confirmed DMD receiving standard of care.
The sponsor cited feasibility challenges in meeting regulatory requirements, recruitment constraints, and projected timelines for study completion and any subsequent Phase III development as the primary reasons for halting recruitment. According to Roche, the decision was not related to new efficacy findings, unanticipated safety signals, or quality concerns.
Decision context
Satralizumab is approved by the US FDA for neuromyelitis optica spectrum disorder and remains in development across multiple inflammatory indications. While the molecule is being withdrawn from development in relation to bone health, Roche said discontinuation of SHIELD DMD does not affect ongoing or planned trials in other disease areas.
Roche was evaluating satralizumab’s ability to target chronic inflammation-driven muscle degeneration and bone fragility/BMD – a major morbidity in DMD that is exacerbated by long-term corticosteroids. The strategy was supported by preclinical literature that provided some evidence in mouse models that IL-6 blockade could potentially produce functional/morphologic improvements. The trial’s focus on lumbar spine BMD Z-score as a primary outcome (at Week 52 in one group) and including muscle function and fracture-related endpoints reflect Roche’s positioning of satralizumab as a therapy to improve bone health (and potentially muscle outcomes) in steroid-treated DMD patients rather than a dystrophin-restoration approach.
The decision to end development likely reflects the complexity of DMD progression and standard-of-care steroids, and the difficulty of proving clinically meaningful benefit on muscle function in heterogeneous populations.
In addition, the competitive landscape for DMD is increasingly dominated by dystrophin-restoration and disease-modifying approaches, as well as recently approved small molecules, examples including:
- Sarepta Therapeutics/Roche’s gene therapy Elevidys (delandistrogene moxeparvovec) was granted accelerated approval in 2023 for a narrow ambulatory age group, with subsequent FDA expansion in 2024 to broader ages (per FDA press announcement)
- Italfarmaco S.p.A.’s Duvyzat (givinostat), a non-steroidal anti-inflammatory HDAC inhibitor that won FDA approval in 2024 for DMD across all genotypes.
- Santhera Pharmaceuticals’ Agamree (vamorolone), a dissociative steroid designed to treat DMD with fewer side effects than traditional corticosteroids, approved in the US in October 2023.